Given the rise in metabolic disease incidence in the US, novel pharmacological strategies for maintaining ERα action during aging, especially in selective metabolic tissues across short-term life phase transitions, e.g., menopause/andropause, could be leveraged to enhance the healthspan of both women and men. This evidence concerns the gene ERAL1 and metabolic disease.